The G-BA, Germany’s top federal health care decision-making body, has published its 2025 work plan, which includes measures to ease the country’s implementation of EU-level joint clinical assessments, which introduced in January under the EU Health Technology Assessment (HTA) Regulation. It will also make a decision on whether clinical guidelines can include off-label treatments for long-Covid-19.
German Agency’s 2025 Plan Highlights EU HTA Reg, Long Covid And Smoking Cessation Drugs
An ordinance came into effect on 8 March to ensure that joint clinical assessments can be incorporated into the German pricing and reimbursement system.
